Jefferies Maintains Buy on Pacira BioSciences, Raises Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Glen Santangelo maintains a Buy rating on Pacira BioSciences and raises the price target from $15 to $18.
September 24, 2024 | 3:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jefferies analyst Glen Santangelo has reaffirmed a Buy rating for Pacira BioSciences and increased the price target from $15 to $18, indicating a positive outlook for the stock.
The increase in the price target from $15 to $18 by Jefferies suggests a positive outlook for Pacira BioSciences. The reaffirmation of the Buy rating indicates confidence in the company's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100